...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Presentation at AACR Meeting April 10-15

 guess a person could sit around for years with hands in their pockets regarding rv , zen & Bti - not much of a strategy there. I've already moved off Bti , rv next/by June & will give zen till October & that will be the end of my biotech plays.

I'll likely sit and wait it out.  Nope, not much of a strategy there.  Big mistake, all of them.  

I suspect BTI will arrive well before Zenith, though I don't expect first dosing in a BTI Phase I until 2024.  And that's what it will take to get it above a buck IMO.


Share
New Message
Please login to post a reply